2023 World Conference on Lung Cancer (Posters)-P1.25. Real-World Data of Completely Resected Lung Adenocarcinoma Harboring Common EGFR Mutation in Japan (CReGYT-01 EGFR study)

P1.25. Real-World Data of Completely Resected Lung Adenocarcinoma Harboring Common EGFR Mutation in Japan (CReGYT-01 EGFR study) - PDF(Slides)

Back to course

Pdf Summary

The CReGYT-01 EGFR study conducted in Japan evaluated real-world data of patients with completely resected lung adenocarcinoma harboring common EGFR mutations. The study included 4181 patients from 21 centers who were enrolled between 2015 and 2018 and had known EGFR status.<br /><br />The study found that adjuvant chemotherapy did not significantly improve prognosis at any pathological stage. CNS metastasis did not adversely affect the performance status at relapse, suggesting it may not impact post-relapse treatment.<br /><br />In terms of treatment, the study compared the use of Osimertinib, a third-generation EGFR inhibitor, to first and second-generation TKIs for post-relapse first-line therapy. The results showed that Osimertinib did not significantly prolong overall survival compared to the first and second-generation TKIs.<br /><br />Additionally, the study observed that pneumonitis, a side effect of TKI treatment, was slightly more common with Osimertinib compared to other generation TKIs, but all pneumonitis cases were considered acceptable.<br /><br />The researchers concluded that most patients with CNS metastasis could be treated after relapse, and first-line treatment with Osimertinib for these patients showed effectiveness with tolerable toxicity. They also emphasized the need for long-term prospective observational studies to further assess the efficacy and safety of Osimertinib as postoperative adjuvant therapy in real-world settings, as it is also used as primary therapy after relapse in Japan.

Asset Subtitle

Shinya Katsumata

Meta Tag

Speaker Shinya Katsumata

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

CReGYT-01 EGFR study

Japan

lung adenocarcinoma

EGFR mutations

adjuvant chemotherapy

CNS metastasis

Osimertinib

TKIs

overall survival

pneumonitis